Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 631 to 640 of 1435 total matches.
A 4-Drug Combination (Viekira Pak) for Hepatitis C
The Medical Letter on Drugs and Therapeutics • Feb 02, 2015 (Issue 1461)
for Viekira Pak recommends ALT monitoring for the
16
The Medical Letter ® Vol. 57 (1461) February 2, 2015 ...
The FDA has approved Viekira Pak (Abbvie), a fixed-dose
combination of two new direct-acting antiviral
agents (ombitasvir, paritaprevir) with the pharmacologic
enhancer ritonavir in one tablet, co-packaged with
a third new direct-acting antiviral agent (dasabuvir) in
a second tablet, for oral treatment of chronic hepatitis
C virus (HCV) genotype 1 infection. Genotype 1 is
responsible for 70-80% of HCV infections in the US.
Metreleptin (Myalept) - A Leptin Analog for Generalized Lipodystrophy
The Medical Letter on Drugs and Therapeutics • Jan 19, 2015 (Issue 1460)
, and 5 mg for patients ≤40 kg,
males >40 kg, and females >40 kg, respectively, andtter ® Vol. 57 (1460 ...
Metreleptin (Myalept – Amylin), a recombinant leptin
analog produced in E. coli, has been approved by the
FDA to treat the complications of leptin deficiency
in patients with congenital or acquired generalized
lipodystrophy. It has not been approved to date for
the treatment of partial lipodystrophies, including
those associated with the use of protease inhibitors in
patients with HIV. Metreleptin is approved in Japan for
the treatment of any lipodystrophy disorder.
Oritavancin (Orbactiv) for Skin and Skin Structure Infections
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
to another
4
The Medical Letter ® Vol. 57 (1459) January 5, 2015
Table 2. Oritavancin Clinical Trials ...
The FDA has approved oritavancin (Orbactiv – The
Medicines Company), a long-acting lipoglycopeptide
antibiotic given as a single intravenous (IV) dose, for
treatment of acute bacterial skin and skin structure
infections caused by susceptible gram-positive
bacteria in adults. It is the third lipoglycopeptide
antibiotic to be marketed in the US; telavancin (Vibativ)
and dalbavancin (Dalvance) were approved earlier.
Olodaterol (Striverdi Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
The Medical Letter ® Vol. 57 (1459) January 5, 2015
DOSAGE AND ADMINISTRATION — Striverdi Respimat ...
Olodaterol (Striverdi Respimat – Boehringer Ingelheim),
a new inhaled long-acting beta2-agonist, has been
approved by the FDA for once-daily maintenance
treatment of airflow obstruction in patients with
chronic obstructive pulmonary disease (COPD). It is
not approved for treatment of acute exacerbations of
COPD or for treatment of asthma. Olodaterol is the third
long-acting beta2-agonist to be approved by the FDA
for once-daily use; indacaterol (Arcapta Neohaler),
which is available as a single agent, and vilanterol,
which is available only in fixed-dose combinations
with the...
Trumenba: A Serogroup B Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
® Vol. 57 (1459) January 5, 2015
including rates of serogroup B disease. In 2012, the
CDC reported 551 ...
The FDA has approved Trumenba (Pfizer), a vaccine
that protects against invasive meningococcal disease
caused by Neisseria meningitidis serogroup B, for use
in adolescents and young adults 10-25 years old.
Triumeq: A 3-Drug Combination for HIV
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
to ...
The FDA has approved Triumeq (Viiv Healthcare),
a fixed-dose combination of the integrase strand
transfer inhibitor (INSTI) dolutegravir and the
nucleoside reverse transcriptase inhibitors (NRTIs)
abacavir and lamivudine, for once-daily treatment of
HIV-1 infection. Dolutegravir (Tivicay) was approved
as a single agent in 2013.
Siltuximab (Sylvant) for Treatment of Multicentric Castleman's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
of response in patients
The Medical Letter ® Vol. 57 (1459) January 5, 2014
Multicentric Castleman ...
The FDA has approved the interleukin-6 (IL-6) antagonist
siltuximab (Sylvant – Janssen), a recombinant
chimeric (human-mouse) monoclonal antibody, for
treatment of multicentric Castleman's disease (MCD) in
patients who are HIV negative and human herpesvirus-8
(HHV-8) negative. It is the first drug to be approved for
this indication.
Invokamet and Xigduo XR - Two New Combinations for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Dec 08, 2014 (Issue 1457)
-term and
have rarely been associated with anemia.
125
The Medical Letter ® Vol. 56 (1457) December 8 ...
The FDA has approved fixed-dose combinations of
metformin with either canagliflozin (Invokamet) or
dapagliflozin (Xigduo XR) for treatment of patients
with type 2 diabetes not adequately controlled
with any one of these drugs, or in those already
being treated with both metformin and either
canagliflozin or dapagliflozin.
Two New Drugs for Idiopathic Pulmonary Fibrosis
The Medical Letter on Drugs and Therapeutics • Dec 08, 2014 (Issue 1457)
-derived growth factor (PDGF),
and fibroblast growth factor (FGF).
124
The Medical Letter ® Vol. 56 ...
The FDA has approved 2 oral drugs for treatment
of idiopathic pulmonary fibrosis (IPF). Pirfenidone
(Esbriet) has been available in Europe since 2011 and
in Canada since 2012. Nintedanib (Ofev) is available
only in the US.
Secondary Prevention of Stroke
The Medical Letter on Drugs and Therapeutics • Dec 08, 2014 (Issue 1457)
of clopidogrel plus
126
The Medical Letter ® Vol. 56 (1457) December 8, 2014
aspirin if that combination ...
Recent guidelines from the American Heart Association
and American Stroke Association reviewed antithrombotic
therapy options for secondary prevention of
stroke in patients who have had a stroke or transient
ischemic attack (TIA).